Shenzhen-based Asia Regenerative Medicine (ARM) has reportedly raised “tens of millions” of renminbi in a pre-Series A+ financing round led by Efung Fund, with participation from True Trust Investment. The proceeds will be used to advance large animal experiments, investigator-initiated trials (ITT), and Investigational New Drug (IND) filing preparations. This strategic funding round aims to accelerate ARM’s development of innovative bioartificial organs.
Use of Proceeds
The funds raised will be directed towards large animal experiments, investigator-initiated trials (ITT), and preparations for Investigational New Drug (IND) filings. These activities are crucial for advancing ARM’s bioartificial organs from the research stage to clinical application, enhancing the company’s ability to address significant unmet medical needs.
Company Background and Development
Founded in 2018, ARM applies stem-cell and tissue engineering device technology in the preparation of implantable bioartificial organs. The company focuses on addressing organ function decline, end-stage disease, and the shortage of organs for transplantation. ARM is currently developing artificial kidneys and artificial pancreases for the treatment of kidney diseases and diabetes, aiming to provide life-changing solutions for patients in need.-Fineline Info & Tech
